Flomics Biotech is excited to announce the launch of its seed investment round of 500.000€.
In the last 2 years Flomics’ team has been working in the fine-tuning and validation of its cell-free RNA liquid biopsy technology that will enable early-stage detection of complex diseases from a standard blood sample.
The new investment round will enable Flomics to further capitalize on its position as leader in the liquid biopsy industry and prepare the launch of its first diagnosis product in the field of colon cancer diagnosis. Constant product innovation is a key area of focus for Flomics. The funding will also drive the development of biomarkers for the early detection of other complex diseases such as lung cancer and further international expansion for Flomics genomics services provider arm.